

Recombinant Human sTRAIL Receptor-1

Catalog # PBG10430

Specification

Recombinant Human sTRAIL Receptor-1 - Product Information

Recombinant Human sTRAIL Receptor-1 - Additional Information

Description

TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain, " which can activate the cell's apoptotic machinery. These receptors are activated by binding to either membrane anchored or soluble TRAIL/Apo2L. Recombinant human soluble TRAIL Receptor-1/DR4 is a 22.7 kDa protein (215 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain.

BiologicalActivity

Measured by its ability to inhibit apoptosis in LN-18 cells. The expected ED₅₀ for this effect is 0.4 -0.5 μ g/ml.

Authenticity Verified by N-terminal and Mass Spectrometry analyses (when applicable).

Endotoxin Endotoxin level is <0.1 ng/ μg of protein (<1EU/ μg).

Protein Content Verified by UV Spectroscopy and/or SDS-PAGE gel.

Storage -20°C

Precautions Recombinant Human sTRAIL Receptor-1 is for research use only and not for use in diagnostic or therapeutic procedures.

Recombinant Human sTRAIL Receptor-1 - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>



Recombinant Human sTRAIL Receptor-1 - Images